Evidence of Abscopal Responses in Patients
Filed with ASX · · 3 pages · English
In the deck
Earlier from Noxopharm
- NOX Reports NOX66 Clinical Data
- Appendix 4D and Half Year Accounts
- NOX closes $4m capital raising for US subsidiary Nyrada Inc
- NOX receives FY17 R&D Tax Rebate
- EOY Guidance on 2018 NOX66 Clinical Development Strategy
Later from Noxopharm
- NOX raises $10.8 M to advance clinical program
- DARRT-1 Clinical Study commences
- St Vincents Hospital study passes first milestone
- NOX CEO interview on Radiotherapy Clinical Programs
- NOX CEO interview on near complete NOX66 chemotherapy trial
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm